EMEA-001407-PIP02-15-M05

Table of contents

Key facts

Invented name
Opdivo
Active substance
nivolumab
Therapeutic area
Oncology
Decision number
P/0237/2021
PIP number
EMEA-001407-PIP02-15-M05
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of malignant neoplasms of lymphoid tissue
  • Treatment of malignant neoplasms of the central nervous system
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

E-mail: medical.information@bms.com
Tel. +44 1423 533 610
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating